AU
UK
CA
US
IND
NZ
Last update at 2026-06-08T20:02:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
Fri 10 Oct 25, 10:30 AMAbbott Laboratories shows growth in core products amid market shifts
Mon 11 Aug 25, 04:07 PMInside Dexcom’s strategy to stay ahead in the $13.6bn CGM market
Thu 07 Aug 25, 09:39 AMIf You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now?
Sun 25 May 25, 02:00 AMAbbott (ABT) Stock Moves -0.15%: What You Should Know
Fri 23 May 25, 09:50 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 8466.00M | 7013.00M | 6664.00M | 8306.00M | 8211.00M |
| Minority interest | - | - | - | - | - |
| Net income | 6524.00M | 13402.00M | 5723.00M | 6933.00M | 7071.00M |
| Selling general administrative | 12378.00M | 11697.00M | 11198.00M | 11012.00M | 11324.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 24607.00M | 21325.00M | 20037.00M | 24511.00M | 24538.00M |
| Reconciled depreciation | 3116.00M | 3218.00M | 3237.00M | 2013.00M | 2047.00M |
| Ebit | 8807.00M | 7616.00M | 7362.00M | 8362.00M | 8425.00M |
| Ebitda | 11553.00M | 10834.00M | 10605.00M | 10696.00M | 10749.00M |
| Depreciation and amortization | 2746.00M | 3218.00M | 3243.00M | 2334.00M | 2324.00M |
| Non operating income net other | - | - | - | 502.00M | 319.00M |
| Operating income | 8048.00M | 6825.00M | 6435.00M | 8362.00M | 8425.00M |
| Other operating expenses | 36280.00M | 35099.00M | 33674.00M | 35291.00M | 34650.00M |
| Interest expense | 341.00M | 603.00M | 698.00M | 375.00M | 490.00M |
| Tax provision | 1942.00M | -6389.00000M | 1027.00M | 1373.00M | 1140.00M |
| Interest income | 135.00M | 344.00M | 384.00M | 377.00M | 491.00M |
| Net interest income | -185.00000M | -215.00000M | -248.00000M | -375.00000M | -490.00000M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1942.00M | -6389.00000M | 941.00M | 1373.00M | 1140.00M |
| Total revenue | 44328.00M | 41950.00M | 40109.00M | 43653.00M | 43075.00M |
| Total operating expenses | 16586.00M | 14474.00M | 13602.00M | 16149.00M | 16113.00M |
| Cost of revenue | 19721.00M | 20625.00M | 20072.00M | 19142.00M | 18537.00M |
| Total other income expense net | 418.00M | 188.00M | 229.00M | -56.00000M | -214.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 6524.00M | 13402.00M | 5162.00M | 6933.00M | 7071.00M |
| Net income applicable to common shares | 6524.00M | 13402.00M | 5723.00M | 6933.00M | 7071.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 86713.00M | 81414.00M | 73214.00M | 74438.00M | 75196.00M |
| Intangible assets | 5526.00M | 6647.00M | 8815.00M | 10454.00M | 12739.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2640.00M | 2570.00M | 2256.00M | 2663.00M | 2346.00M |
| Total liab | 33942.00M | 33513.00M | 34387.00M | 37533.00M | 39172.00M |
| Total stockholder equity | 52130.00M | 47664.00M | 38603.00M | 36686.00M | 35802.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 8378.00M | 7614.00M | 7729.00M | 8631.00M | 7943.00M |
| Common stock | 25527.00M | 25153.00M | 24869.00M | 24709.00M | 24470.00M |
| Capital stock | 25527.00M | 25153.00M | 24869.00M | 24709.00M | 24470.00M |
| Retained earnings | 49781.00M | 47261.00M | 37554.00M | 35257.00M | 31528.00M |
| Other liab | - | - | - | 6579.00M | 7815.00M |
| Good will | 24035.00M | 23108.00M | 23679.00M | 22799.00M | 23231.00M |
| Other assets | 17296.00M | 15384.00M | 5975.00M | 4917.00M | 4059.00M |
| Cash | 8522.00M | 7616.00M | 6896.00M | 9882.00M | 9799.00M |
| Cash and equivalents | 8522.00M | 7616.00M | 6896.00M | 9882.00M | 9799.00M |
| Total current liabilities | 16496.00M | 14157.00M | 13841.00M | 15489.00M | 13105.00M |
| Current deferred revenue | - | - | 174.00M | - | - |
| Net debt | 6545.00M | 7659.00M | 8977.00M | 7834.00M | 9207.00M |
| Short term debt | 3309.00M | 1754.00M | 1325.00M | 2251.00M | 754.00M |
| Short long term debt | 3033.00M | 1500.00M | 1080.00M | 2251.00M | 754.00M |
| Short long term debt total | 15067.00M | 15275.00M | 15873.00M | 17716.00M | 19006.00M |
| Other stockholder equity | -17177.00000M | -16844.00000M | -15981.00000M | -15229.00000M | -11822.00000M |
| Property plant equipment | 12942.00M | 11733.00M | 11276.00M | 9162.00M | 8959.00M |
| Total current assets | 25996.00M | 23656.00M | 22670.00M | 25224.00M | 24239.00M |
| Long term investments | 918.00M | 886.00M | 799.00M | 766.00M | 816.00M |
| Net tangible assets | - | - | - | 10955.00M | -2189.00000M |
| Short term investments | 417.00M | 351.00M | 383.00M | 288.00M | 450.00M |
| Net receivables | 7929.00M | 6925.00M | 6565.00M | 8881.00M | 6487.00M |
| Long term debt | 9896.00M | 12625.00M | 13599.00M | 14522.00M | 17296.00M |
| Inventory | 6488.00M | 6194.00M | 6570.00M | 6173.00M | 5157.00M |
| Accounts payable | 4240.00M | 4195.00M | 4295.00M | 4607.00M | 4408.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | 219.00M | 222.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -6001.00000M | -7906.00000M | -7839.00000M | -8051.00000M | -8374.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 24709.00M | 24470.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | 35257.00M | 31528.00M |
| Treasury stock | - | - | - | - | -11822.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 17296.00M | 15384.00M | 5975.00M | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 60717.00M | 57758.00M | 50544.00M | 49214.00M | 50957.00M |
| Capital lease obligations | 931.00M | 896.00M | 949.00M | 943.00M | 956.00M |
| Long term debt total | 9896.00M | 12625.00M | 13599.00M | 14522.00M | 17296.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -164.00000M | -2338.00000M | -2941.00000M | -33.00000M | -96.00000M |
| Change to liabilities | - | - | - | 37.00M | 380.00M |
| Total cashflows from investing activities | -2422.00000M | -2338.00000M | -3133.00000M | -1740.00000M | -2008.00000M |
| Net borrowings | -1614.00000M | -537.00000M | -2475.00000M | 47.00M | -248.00000M |
| Total cash from financing activities | -6309.00000M | -5404.00000M | -7091.00000M | -7636.00000M | -5494.00000M |
| Change to operating activities | - | - | - | -75.00000M | -312.00000M |
| Net income | 6524.00M | 13402.00M | 5723.00M | 6933.00M | 7071.00M |
| Change in cash | 906.00M | 720.00M | -2986.00000M | 83.00M | 2961.00M |
| Begin period cash flow | 7616.00M | 6896.00M | 9882.00M | 9799.00M | 6838.00M |
| End period cash flow | 8522.00M | 7616.00M | 6896.00M | 9882.00M | 9799.00M |
| Total cash from operating activities | 9566.00M | 8558.00M | 7261.00M | 9581.00M | 10533.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 3116.00M | 3218.00M | 3243.00M | 3267.00M | 3538.00M |
| Other cashflows from investing activities | 18.00M | 9.00M | 22.00M | 70.00M | -27.00000M |
| Dividends paid | 4116.00M | 3836.00M | 3556.00M | -3309.00000M | -3202.00000M |
| Change to inventory | 195.00M | -58.00000M | -232.00000M | -1413.00000M | -456.00000M |
| Change to account receivables | -652.00000M | -691.00000M | -356.00000M | -68.00000M | -383.00000M |
| Sale purchase of stock | -893.00000M | -1295.00000M | -1227.00000M | -3795.00000M | -2299.00000M |
| Other cashflows from financing activities | -82.00000M | 264.00M | 167.00M | 221.00M | 55.00M |
| Change to netincome | - | - | - | 685.00M | 640.00M |
| Capital expenditures | 2171.00M | 2207.00M | 2202.00M | 1777.00M | 1885.00M |
| Change receivables | - | - | - | -68.00000M | -383.00000M |
| Cash flows other operating | - | - | - | 140.00M | -257.00000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | 205.00M | 3031.00M |
| Change in working capital | -803.00000M | -9217.00000M | -2475.00000M | -1519.00000M | -771.00000M |
| Stock based compensation | 664.00M | 673.00M | 644.00M | 685.00M | 640.00M |
| Other non cash items | 65.00M | 482.00M | 126.00M | 215.00M | 55.00M |
| Free cash flow | 7395.00M | 6351.00M | 5059.00M | 7804.00M | 8648.00M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories |
-0.57 0.63% | 90.50 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
-4.13 1.35% | 301.53 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-0.98 1.20% | 80.69 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
0.15 0.31% | 48.70 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
| SEMHF Siemens Healthineers AG |
-0.395 1.01% | 38.64 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. The company also provides cancer screening and diagnostic test products. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Labor
100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert B. Ford | Chairman, Pres & CEO | 1974 |
| Mr. Robert E. Funck Jr. | Exec. VP of Fin. & CFO | 1961 |
| Mr. Hubert L. Allen | Exec. VP, Gen. Counsel & Sec. | 1966 |
| Mr. Daniel Gesua Sive Salvadori | Exec. VP and Group Pres of Established Pharmaceuticals & Nutritional Products | 1979 |
| Ms. Andrea F. Wainer | Exec. VP of Rapid & Molecular Diagnostics | 1970 |
| Mr. Scott Michael Leinenweber | VP of Investor Relations, Licensing & Acquisitions | 1972 |
| James E. Young | VP and Chief Ethics & Compliance Officer | NA |
| Ms. Melissa Brotz | VP of Public Affairs & Corp. Marketing | NA |
| Ms. Elaine R. Leavenworth | Sr. VP and Chief Marketing & External Affairs Officer | 1959 |
| Ms. Mary K. Moreland | Exec. VP of HR | 1966 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...